Itskovitz H D, Krug K, Khoury S, Mollura J L
Department of Medicine, New York Medical College, Valhalla 10595.
Am J Med. 1989 Jan 23;86(1B):82-6. doi: 10.1016/0002-9343(89)90138-1.
The efficacy and tolerability of the alpha-blocker prazosin was compared with that of atenolol, a beta-blocker, in the long-term treatment of uncomplicated, essential hypertension. Twelve patients were randomly assigned to prazosin treatment and 15 to treatment with atenolol. Drug therapy was titrated to reduce diastolic blood pressure by 10 mm Hg or to below 89 mm Hg, whichever was lower. If monotherapy with either study drug failed to do this, hydrochlorothiazide was added to the regimen. Once blood pressure control was established, patients received maintenance therapy at that dosage and were followed for up to 12 months. Blood pressure, side effects, and plasma lipid levels were monitored during this period. Seventy-five percent of patients receiving prazosin monotherapy attained blood pressure goals, compared with 60 percent of patients given atenolol monotherapy. With the addition of low-dose hydrochlorothiazide, those patients not having an adequate response to monotherapy attained blood pressure control. Blood pressure reductions were maintained without dosage adjustment throughout the maintenance period; patient acceptance was good, and there was no evidence of tolerance. Treatment with atenolol produced slight increases in plasma triglyceride levels and little change in total or low-density lipoprotein cholesterol. In contrast, patients treated with prazosin demonstrated no adverse effects with regard to lipid levels. Although a higher percentage of patients reached goal blood pressure with prazosin monotherapy than with atenolol, the response rates were comparable when hydrochlorothiazide was added to the regimens.
在对单纯性原发性高血压的长期治疗中,将α受体阻滞剂哌唑嗪与β受体阻滞剂阿替洛尔的疗效和耐受性进行了比较。12名患者被随机分配接受哌唑嗪治疗,15名患者接受阿替洛尔治疗。药物治疗进行滴定调整,以使舒张压降低10毫米汞柱或降至89毫米汞柱以下,以较低者为准。如果使用任何一种研究药物进行单一疗法未能达到这一目标,则在治疗方案中添加氢氯噻嗪。一旦确立血压控制,患者就以该剂量接受维持治疗,并随访长达12个月。在此期间监测血压、副作用和血脂水平。接受哌唑嗪单一疗法的患者中有75%达到了血压目标,而接受阿替洛尔单一疗法的患者中这一比例为60%。添加低剂量氢氯噻嗪后,那些对单一疗法反应不足的患者实现了血压控制。在整个维持期内,无需调整剂量即可维持血压降低;患者接受度良好,且没有耐受性的证据。阿替洛尔治疗使血浆甘油三酯水平略有升高,总胆固醇或低密度脂蛋白胆固醇几乎没有变化。相比之下,接受哌唑嗪治疗的患者在血脂水平方面未显示出不良反应。虽然接受哌唑嗪单一疗法达到目标血压的患者比例高于阿替洛尔,但当在治疗方案中添加氢氯噻嗪时,两者的有效率相当。